Healthcare provider profile · identity verified

Robb E Kline, MD

Family Practice · LA CROSSE, WI · NPI 1972509222

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	344	88
Lisinopril	Lisinopril	227	59
Omeprazole	Omeprazole	216	51
Amlodipine Besylate	Amlodipine Besylate	201	54
Rosuvastatin Calcium	Rosuvastatin Calcium	198	52
Metoprolol Succinate	Metoprolol Succinate	182	47
Metformin Hcl Er	Metformin Hcl	174	44
Tamsulosin Hcl	Tamsulosin Hcl	167	42
Levothyroxine Sodium	Levothyroxine Sodium	159	29
Gabapentin	Gabapentin	130	26
Losartan Potassium	Losartan Potassium	128	28
Albuterol Sulfate Hfa	Albuterol Sulfate	120	50
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	104	22
Eliquis	Apixaban	87	18
Trulicity	Dulaglutide	82	12
Hydrochlorothiazide	Hydrochlorothiazide	81	28
Duloxetine Hcl	Duloxetine Hcl	78	13
Tramadol Hcl	Tramadol Hcl	71	20
Metoprolol Tartrate	Metoprolol Tartrate	69	18
Potassium Chloride	Potassium Chloride	68	18
Pantoprazole Sodium	Pantoprazole Sodium	67	11
Trazodone Hcl	Trazodone Hcl	65	18
Fluoxetine Hcl	Fluoxetine Hcl	61	17
Sertraline Hcl	Sertraline Hcl	60	13
Simvastatin	Simvastatin	59	15
Furosemide	Furosemide	58	19
Metformin Hcl	Metformin Hcl	58	14
Alprazolam	Alprazolam	54	suppressed
Glipizide Er	Glipizide	50	12
Fluticasone Propionate	Fluticasone Propionate	48	20
Ozempic	Semaglutide	47	11
Oxybutynin Chloride Er	Oxybutynin Chloride	46	suppressed
Divalproex Sodium	Divalproex Sodium	42	suppressed
Mirtazapine	Mirtazapine	42	suppressed
Allopurinol	Allopurinol	40	11
Quetiapine Fumarate	Quetiapine Fumarate	36	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	36	suppressed
Donepezil Hcl	Donepezil Hcl	35	suppressed
Warfarin Sodium	Warfarin Sodium	34	suppressed
Breo Ellipta	Fluticasone/Vilanterol	33	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	33	suppressed
Incruse Ellipta	Umeclidinium Bromide	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	33	21
Finasteride	Finasteride	32	suppressed
Montelukast Sodium	Montelukast Sodium	32	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	31	suppressed
Carvedilol	Carvedilol	31	suppressed
Memantine Hcl	Memantine Hcl	30	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Farxiga	Dapagliflozin Propanediol	29	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	suppressed
Chlorthalidone	Chlorthalidone	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	14
Oxycodone Hcl	Oxycodone Hcl	27	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Famotidine	Famotidine	25	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Irbesartan	Irbesartan	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Divalproex Sodium Er	Divalproex Sodium	22	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Jardiance	Empagliflozin	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Spiriva Handihaler	Tiotropium Bromide	21	suppressed
Ketoconazole	Ketoconazole	20	suppressed
Pregabalin	Pregabalin	19	suppressed
Zonisamide	Zonisamide	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	18	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Loperamide	Loperamide Hcl	18	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	11
Prednisone	Prednisone	17	11
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Testosterone Cypionate	Testosterone Cypionate	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Atenolol	Atenolol	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Ventolin Hfa	Albuterol Sulfate	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Baclofen	Baclofen	13	suppressed
Galantamine Er	Galantamine Hbr	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Potassium Citrate Er	Potassium Citrate	13	suppressed
Temazepam	Temazepam	13	suppressed
Varenicline Tartrate	Varenicline Tartrate	13	suppressed
Digoxin	Digoxin	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error